Literature DB >> 24858470

Development of an analytical procedure for quantifying the underivatized neurotoxin β-N-methylamino-L-alanine in brain tissues.

Audrey Combes1, Saïda El Abdellaoui, Jérome Vial, Emmeline Lagrange, Valérie Pichon.   

Abstract

The cyanotoxin β-methylamino-L-alanine (BMAA) has received renewed attention as an environmental risk factor for sporadic cases of amyotrophic lateral sclerosis (ALS) (Nunn et al., Brain Res 410:375-379, 1987). The aim of the present study was to develop and to validate an analytical procedure that allows the quantification of native BMAA and of its natural isomer, 2,4 diaminobutyric acid (DAB), in brain tissues. An analytical procedure was previously reported by our group for the determination of underivatized BMAA in environmental samples. It included a step of sample clean-up by solid phase extraction (SPE) with a mixed-mode sorbent and the analyses were performed by LC/MS-MS using hydrophilic interaction chromatography and multiple reactions monitoring scan mode. As brain tissues have a higher lipid content, the crucial step of sample clean-up had been optimized by evaluating the efficiency of the addition of a liquid/liquid extraction step prior to the SPE procedure or alternatively, of washing steps to the SPE extraction procedure. The efficiency was checked by visualizing the complexity of the resulting chromatograms in LC/MS and their performance by using spiked brain samples. The optimized analytical procedure, including a washing step with cyclohexane to the SPE with a recovery yield close to 100%, was validated using the total error approach and allowed the quantification of BMAA in a concentration level ranging from 20 to 1,500 ng/g in brain samples. Finally, the feasibility of implementation of this procedure was verified in human brain samples from two patients who died of ALS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24858470     DOI: 10.1007/s00216-014-7872-y

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  6 in total

Review 1.  A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.

Authors:  N Chernoff; D J Hill; D L Diggs; B D Faison; B M Francis; J R Lang; M M Larue; T-T Le; K A Loftin; J N Lugo; J E Schmid; W M Winnik
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2017-06-09       Impact factor: 6.393

2.  UPLC-ESI-MS/MS method for the quantitative measurement of aliphatic diamines, trimethylamine N-oxide, and β-methylamino-l-alanine in human urine.

Authors:  Deepak Bhandari; Brett A Bowman; Anish B Patel; David M Chambers; Víctor R De Jesús; Benjamin C Blount
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-02       Impact factor: 3.205

3.  Spatio-temporal clustering of amyotrophic lateral sclerosis in France: A population-based study.

Authors:  Farid Boumédiene; Benoît Marin; Jaime Luna; Vincent Bonneterre; William Camu; Emmeline Lagrange; Gérard Besson; Florence Esselin; Elisa De La Cruz; Géraldine Lautrette; Pierre Marie Preux; Philippe Couratier
Journal:  Eur J Epidemiol       Date:  2022-09-13       Impact factor: 12.434

4.  Is Exposure to BMAA a Risk Factor for Neurodegenerative Diseases? A Response to a Critical Review of the BMAA Hypothesis.

Authors:  Dunlop Ra; Banack Sa; Bishop Sl; Metcalf Js; Murch Sj; Davis DA; Stommel Ew; Karlsson O; Brittebo Eb; Chatziefthimiou Ad; Tan Vx; Guillemin Gg; Cox Pa; Mash Dc; Bradley Wg
Journal:  Neurotox Res       Date:  2021-02-06       Impact factor: 3.911

5.  A Collaborative Evaluation of LC-MS/MS Based Methods for BMAA Analysis: Soluble Bound BMAA Found to Be an Important Fraction.

Authors:  Elisabeth J Faassen; Maria G Antoniou; Wendy Beekman-Lukassen; Lucie Blahova; Ekaterina Chernova; Christophoros Christophoridis; Audrey Combes; Christine Edwards; Jutta Fastner; Joop Harmsen; Anastasia Hiskia; Leopold L Ilag; Triantafyllos Kaloudis; Srdjan Lopicic; Miquel Lürling; Hanna Mazur-Marzec; Jussi Meriluoto; Cristina Porojan; Yehudit Viner-Mozzini; Nadezda Zguna
Journal:  Mar Drugs       Date:  2016-02-29       Impact factor: 5.118

6.  β-methylamino-L-alanine (BMAA) is not found in the brains of patients with confirmed Alzheimer's disease.

Authors:  Julie P Meneely; Olivier P Chevallier; Stewart Graham; Brett Greer; Brian D Green; Christopher T Elliott
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.